International Journal of Laboratory Hematology最新文献

{"title":"Increased Platelet Size and Elevated P2Y12 mRNA Expression Levels in Patients With Diabetes Mellitus","authors":"Masako Nishikawa, Yutaka Nagura, Hitoshi Okazaki, Makoto Kurano, Yutaka Yatomi","doi":"10.1111/ijlh.14372","DOIUrl":"https://doi.org/10.1111/ijlh.14372","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening","authors":"Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, Maël Heiblig, Maxime Jullien, Baptiste Le Calvez, Camille Richard, Valentin Le Roc'h, Emmanuelle Rault, Olivier Hérault, Pierre Peterlin, Alice Garnier, Patrice Chevallier, Simon Bouzy, Yannick Le Bris, Antoine Néel, Julie Graveleau, Olivier Kosmider, Perrine Paul‐Gilloteaux, Nicolas Normand, Marion Eveillard","doi":"10.1111/ijlh.14368","DOIUrl":"https://doi.org/10.1111/ijlh.14368","url":null,"abstract":"IntroductionVEXAS is a syndrome described in 2020, caused by mutations of the <jats:italic>UBA1</jats:italic> gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack significance to discriminate VEXAS from other inflammatory conditions at the screening step. This work hence first focused on singling out dysplastic features indicative of the syndrome among peripheral blood (PB) polymorphonuclears (PMN). A deep learning algorithm is then proposed for automatic detection of these features.MethodsA multicentric dataset, comprising 9514 annotated PMN images was gathered, including <jats:italic>UBA1</jats:italic> mutated VEXAS (<jats:italic>n</jats:italic> = 25), <jats:italic>UBA1</jats:italic> wildtype myelodysplastic (<jats:italic>n</jats:italic> = 14), and <jats:italic>UBA1</jats:italic> wildtype cytopenic patients (<jats:italic>n</jats:italic> = 25). Statistical analysis on a subset of patients was performed to screen for significant abnormalities. Detection of these features on PB was then automated with a convolutional neural network (CNN) for multilabel classification.ResultsSignificant differences were observed in the proportions of PMNs with pseudo‐Pelger, nuclear spikes, vacuoles, and hypogranularity between patients with VEXAS and both cytopenic and myelodysplastic controls.Automatic detection of these abnormalities yielded AUCs in the range [0.85–0.97] and a F1‐score of 0.70 on the test set. A VEXAS screening score was proposed, leveraging the model outputs and predicting the <jats:italic>UBA1</jats:italic> mutational status with 0.82 sensitivity and 0.71 specificity on the test patients.ConclusionThis study suggests that computer‐assisted analysis of PB smears, focusing on suspected VEXAS cases, can provide valuable insights for determining which patients should undergo molecular testing. The presented deep learning approach can help hematologists direct their suspicions before initiating further analyses.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab‐Treated Patients With Multiple Myeloma","authors":"Suwen Yang, Qianwen Hu, Xiaofen Wang, Sai Qiao, Chao Qi, Hong Jin, Yuhong Zhong","doi":"10.1111/ijlh.14366","DOIUrl":"https://doi.org/10.1111/ijlh.14366","url":null,"abstract":"IntroductionAnti‐CD38 therapeutic modalities (e.g., daratumumab) can impede classical CD38 and CD138 gating use for plasma cell (PC) detection in multiple myeloma (MM) patients with minimal residual disease (MRD). We assessed the applicability of CD229, CD269, and interferon regulatory factor (IRF‐4) for PC detection in MM MRD patients.MethodsBone marrow samples were collected from patients with MM. Through multiparameter flow cytometry, we evaluated the suitability of CD229, CD269, and IRF‐4 for distinguishing PCs from other hematopoietic cells and compared their expression pattern on normal PCs (nPCs) and aberrant PCs (aPCs). We also assessed IRF‐4 expression stability after sample storage under different conditions. A 10‐color MRD antibody panel was used to determine whether IRF‐4 is an alternative primary PC‐gating marker for MM MRD assessment.ResultsIRF‐4 was expressed specifically on all PCs; its mean fluorescence intensity (MFI) was highest on PCs among all hematopoietic cells. This MFI did not decrease even after sample storage at 4°C or 25°C for 72 h. In all 42 MRD assessment samples, except for samples (<jats:italic>n</jats:italic> = 10) with no PCs, the use of IRF‐4 enabled accurate nPC (<jats:italic>n</jats:italic> = 12), aPC (<jats:italic>n</jats:italic> = 13), and nPC + aPC (<jats:italic>n</jats:italic> = 7) identification. Even samples from daratumumab‐treated patients had high IRF‐4 MFI, with no difference between pre‐treatment and post‐treatment (<jats:italic>n</jats:italic> = 7; <jats:italic>p</jats:italic> = 0.610).ConclusionsIRF‐4 demonstrates high MFI on PCs, and it is not expressed on other leukocytes. In MM patients with MRD, daratumumab treatment does not affect IRF‐4 expression. IRF‐4 is a promising marker for PC identification in MRD assessment of MM patients undergoing anti‐CD38 therapy.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel TNFRSF13B frameshift variant in one family with lymphoid neoplasms","authors":"Jing Li, Huici Gu, Shu Zhang, Xiaobo Mao, Junyan Zou, Xiaopeng Zhang, Guangxin Peng","doi":"10.1111/ijlh.14359","DOIUrl":"https://doi.org/10.1111/ijlh.14359","url":null,"abstract":"","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frozen/Thawed Samples Can Replace Fresh Samples for Assignment of ISI to Secondary Thromboplastin Standards for Multiple Reagent/Instrument Combinations: Data to Support Possible Revision of WHO Guidelines","authors":"Matthew Kitchen, Michelle Bryant, Paula Brown, Anita Woolley, Steve Kitchen","doi":"10.1111/ijlh.14369","DOIUrl":"https://doi.org/10.1111/ijlh.14369","url":null,"abstract":"BackgroundCalibration of thromboplastins is required for accurate calculation of the international normalised ratio (INR). Accurate INR results are required for optimal dosing of vitamin K antagonists. Decreases in vitamin K antagonist usage have made the recruitment of sample sets for international sensitivity index (ISI) calibrations more difficult. A possible solution to this would be to allow the use of frozen–thawed samples in place of fresh plasmas in the calibration of secondary standards.ObjectivesWe investigated the effect of freezing and thawing samples before usage in ISI calibrations of secondary standards.MethodsMultiple reagent/instruments were tested to identify the degree of difference between a fresh sample ISI calibration and one performed on frozen–thawed samples. Where possible, the two ISI calibrations were performed on the same sample set. Alternatively, a separate set of samples from different patients was used.ResultsThe difference in ISI values was &lt;3% for those datasets where the same samples were used, and &lt;6% for those datasets where two sample sets were used. Additionally, other parameters required for a valid ISI calibration showed only minor differences—some calibrations showed fewer outliers in the frozen–thawed datasets. Mean normal prothrombin time for the international reference thromboplastins was &lt;3.5% different across four different calibrations (two for rabbit thromboplastin and two for recombinant human thromboplastin).ConclusionsThis modification to the WHO guidelines would facilitate the recruitment of test plasmas in advance of calibration solving the problem of requiring availability of fresh patient samples with a range of INRs in a 5‐h window.Trial Registration: Not a part of any clinical trial.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142260779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes","authors":"Alessio Lusci Gemignani, Robel Papotti, Riccardo Bomben, Valter Gattei, Samantha Pozzi, Valentina Donati, Stefania Bettelli, Elisa Forti, Giovanna Mansueto, Arianna Di Napoli, Maria Christina Cox, Leonardo Flenghi, Pietro Rossi, Guido Volpe, Dimitri Dardanis, Clara Bono, Francesca Guerrini, Riccardo Morganti, Stefano Sacchi, Sara Galimberti","doi":"10.1111/ijlh.14363","DOIUrl":"https://doi.org/10.1111/ijlh.14363","url":null,"abstract":"IntroductionEpigenetics has been shown to be relevant in oncology: <jats:italic>BMI1</jats:italic> overexpression has been reported in leukemias, <jats:italic>EZH2</jats:italic> mutations have been found in follicular lymphoma, and <jats:italic>USP22</jats:italic> seems to stabilize BMI1 protein. In this study, we measured the expression of <jats:italic>BMI1, EZH2</jats:italic>, and <jats:italic>USP22</jats:italic> in lymph nodes from 56 diffuse large B‐cell lymphoma (DLBCL) patients.MethodsA new multiplex digital droplet PCR (ddPCR) has been set up to measure the expression of 4 genes (<jats:italic>BMI1, EZH2, USP22</jats:italic>, and <jats:italic>GAPDH</jats:italic>) in the same reaction on RNA extracted from paraffin‐embedded tissues.ResultsThe specificity of ddPCR was confirmed by a 100% alignment on the BLAST platform and its repeatability demonstrated by duplicates. A strict correlation between expression of <jats:italic>BMI1</jats:italic> and <jats:italic>EZH2</jats:italic> and <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> has been found, and high expression of these genes was correlated with extra‐nodal lymphomas. Progression‐free survival (PFS) and overall survival (OS) were conditioned by IPI, bone marrow infiltration, and the complete response achievement. High levels of <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> did not condition the response to therapy, but impaired the PFS, especially for patients defined at “high risk” based on the cell of origin (no germinal center [GCB]), high BCL2 expression, and IPI 3‐5. In this subgroup, the probability of relapse/progression was twice higher than that of patients carrying low <jats:italic>BMI1</jats:italic> and <jats:italic>USP22</jats:italic> levels.ConclusionHigh expression of <jats:italic>BMI1</jats:italic> and of <jats:italic>USP22</jats:italic> might be a poor prognostic factor in DLBCL, and might represent the target for novel inhibitors.","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142218227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunophenotypic features of early haematopoietic and leukaemia stem cells","authors":"Tom Reuvekamp,&nbsp;Costa Bachas,&nbsp;Jacqueline Cloos","doi":"10.1111/ijlh.14348","DOIUrl":"10.1111/ijlh.14348","url":null,"abstract":"<p>Many tumours are organised in a hierarchical structure with at its apex a cell that can maintain, establish, and repopulate the tumour—the cancer stem cell. The haematopoietic stem cell (HSC) is the founder cell for all functional blood cells. Like HSCs, the leukaemia stem cells (LSC) are hypothesised to be the leukaemia-initiating cells, which have features of stemness such as self-renewal, quiescence, and resistance to cytotoxic drugs. Immunophenotypically, CD34+CD38− defines HSCs by adding lineage negativity and CD90+CD45RA−. At which stage of maturation the further differentiation is blocked, determines the type of leukaemia, and determines the immunophenotype of the LSC specific to the leukaemia type. No apparent LSC phenotype has been described in lymphoid leukaemia, and it is debated if a specific acute lymphocytic leukaemia-initiating cell is present, as all cells are capable of engraftment in a secondary mouse model. In chronic lymphocytic leukaemia, a B-cell clone is responsible for uncontrolled proliferation, not a specific LSC. In chronic and acute myeloid leukaemia, LSC is described as CD34+CD38− with the expression of a marker that is aberrantly expressed (LSC marker), such as CD45RA, CD123 or in the case of chronic myeloid leukaemia CD26. In acute myeloid leukaemia, the LSC load had prognostic relevance and might be a biomarker that can be used for monitoring and as an addition to measurable residual disease. However, challenges such as the CD34-negative immunophenotype need to be explored.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests","authors":"D. M. Adcock,&nbsp;G. W. Moore,&nbsp;G. W. Kershaw,&nbsp;S. A. L. Montalvao,&nbsp;R. C. Gosselin","doi":"10.1111/ijlh.14344","DOIUrl":"10.1111/ijlh.14344","url":null,"abstract":"<p>This guidance document has been prepared on behalf of the International Council for Standardization in Haematology (ICSH). The aim of the document is to provide guidance and recommendations for the performance and interpretation of activated partial thromboplastin time (APTT) and prothrombin time (PT) plasma mixing tests in clinical laboratories in all regions of the world. The following areas are included in this document: preanalytical, analytical, postanalytical, and quality assurance considerations as they relate to the proper performance and interpretation of plasma mixing tests. The recommendations are based on good laboratory practice, published data in peer-reviewed literature, and expert opinion.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14344","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"F2c.*C20209T mutation in patients with a history of thrombosis: A case report, retrospective 2 site-results and review of the literature","authors":"Didier Jambou,&nbsp;Noemie Saut,&nbsp;Viviane Queyrel,&nbsp;Anny Appert-Flory,&nbsp;Florence Fischer,&nbsp;Pierre Suchon,&nbsp;Neila De Pooter,&nbsp;Pierre Toulon","doi":"10.1111/ijlh.14312","DOIUrl":"10.1111/ijlh.14312","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>G20210A (c.*97G&gt;A) prothrombin gene variant, found in white population has been associated with an increased risk of venous thromboembolism (VTE). Other rare polymorphisms in F2 gene (C20209T) have been reported, more rare and touching black people, but its potential association with VTE remain uncertain.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>About a 69 years-old Caucasian woman presenting an unprovoked deep venous thrombosis of the leg, we analyzed retrospectively 25.000 thrombophilia tests on a 11-year period of time (2007–2018), at Nice and Marseille University Hospitals, and performed extensive review of the literature.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Genetic determination included a similar PCR protocol and sequencing. Twenty-one heterozygous cases out of 25.585 determinations (0.08%) was found. The C20209T mutation detected in our Caucasian patient is rare, with a frequency that differed from what was reported in the previous literature, mainly in non-Caucasian patients (Africans, Africans-Americans, and Caribbeans). One hundred and thirteen patients with this mutation have been described in the literature, of which only one homozygous.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study is the most important on C20209T mutation performed at present, allowing to precise its frequency and its potential role in venous thromboembolism.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14312","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone marrow necrosis: Facts, controversies, and perspective","authors":"Chengxin Luan,&nbsp;Hongguo Zhao,&nbsp;Yufei Ding","doi":"10.1111/ijlh.14335","DOIUrl":"10.1111/ijlh.14335","url":null,"abstract":"<p>Bone marrow necrosis (BMN) is a clinically and pathologically poorly-defined and readily-overlooked entity. The current facts and guidelines pertaining to this entity are scarce, and there exist controversies. Upon reviewing the literature, we present the facts, analyze these controversies, and discourse on future prospects.</p>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ijlh.14335","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}